cerecin_logo_rgb.jpg
Cerecin Announces Orphan Drug Designation from U.S. FDA for Tricaprilin in the Treatment of Infantile Spasms
October 29, 2020 08:00 ET | Cerecin
SINGAPORE AND DENVER, COLORADO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced today that the U.S. Food...
cerecin_logo_rgb.jpg
U.S. FDA Grants Rare Pediatric Disease Designation to Cerecin’s Investigational Drug Tricaprilin for the Treatment of Infantile Spasms
October 08, 2020 04:48 ET | Cerecin
SINGAPORE AND DENVER, COLORADO , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cerecin, a biopharmaceutical company focused on discovering and developing brain therapeutics, announced that the U.S. Food and...
cerecin_logo_rgb.jpg
Cerecin appoints biotech veteran Joseph S. Zakrzewski as its new Chairman
December 20, 2019 05:15 ET | Cerecin
SINGAPORE AND DENVER, COLORADO, Dec. 20, 2019 (GLOBE NEWSWIRE) -- SINGAPORE AND DENVER, COLORADO, 20 December 2019 – Cerecin, an innovative biopharmaceutical company focused on brain health, today...
Bruce Morimoto
 Cerecin strengthens its leadership position in CNS drug development by adding a biotech veteran to the executive team Bruce Morimoto joins Cerecin as Vice President of Drug Development
November 04, 2019 05:00 ET | Cerecin
Denver, Colorado, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecin, a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world, today announced...
Xiaoping_Image
Cerecin appoints Dr. Xiaoping Cao as Head of CMC
January 07, 2019 02:00 ET | Cerecin
Singapore, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cerecin appoints Dr. Xiaoping Cao as Head of CMC Dr. Cao will lead the Chemistry, Manufacturing and Controls (CMC) of Cerecin’s pipeline of highly...